A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer Academic Article uri icon

Overview

MeSH Major

  • Metformin
  • Neoplastic Stem Cells
  • Pancreatic Neoplasms

abstract

  • When administered concurrently with IMRT, erlotinib 100 mg daily and capecitabine 800 mg/m(2) twice daily (Monday to Friday) can be administered safely in resected pancreas cancer patients, and is the recommended regimen for efficacy studies using this regimen.

publication date

  • January 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3000462

Digital Object Identifier (DOI)

  • 10.1593/tlo.10196

PubMed ID

  • 21151476

Additional Document Info

start page

  • 373

end page

  • 9

volume

  • 3

number

  • 6